You are here

Article Text

Article menu
Download PDFPDF
ePoster
EP923 Smoothened protein expression and promoter methylation status in serous ovarian carcinomas
  1. P Mioc1,
  2. V Karin Kujundzic1,2,
  3. R Matijevic3,4,
  4. A Skrtic2,5,6,
  5. S Vranic7 and
  6. L Serman1,2
  1. 1Department of Biology, School of Medicine, University of Zagreb
  2. 2Centre of Excellence in Reproductive and Regenerative Medicine, School of Medicine, University of Zagreb
  3. 3Department of Obstetrics and Gynecology, School of Medicine, University of Zagreb
  4. 4Department of Obstetrics and Gynecology, University Hospital Merkur
  5. 5Department of Pathology, School of Medicine, University of Zagreb
  6. 6Department of Pathology, University Hospital Merkur, Zagreb, Croatia
  7. 7College of Medicine, QU Health, Qatar University, Doha, Qatar

Abstract

Introduction/Background Aberrant Hedgehog (Hh) pathway signaling has been implicated in pathogenesis of several human cancers. Recent studies have indicated its active role in serous ovarian carcinomas. Smoothened protein (SMO), a transmembrane co-receptor in Hh pathway signal transduction, is inhibited in non-dividing cells, thus its disinhibition might be a trigger for uncontrolled cell proliferation and growth. Very few studies have explored the role of SMO in serous ovarian cancers. The aim of the study was to assess the expression of SMO protein and to explore the Smoothened gene promoter methylation in a cohort of serous ovarian carcinomas.

Methodology SMO protein expression was immunohistochemically quantified in 40 high-grade serous carcinomas (HGSC), 12 low-grade serous carcinomas (LGSC), 20 normal ovarian and 9 normal fallopian tube samples (controls). SMO gene promoter methylation status was analyzed using methylation-specific polymerase chain reaction (MSP) in randomly selected HGSCs (n=10), LGSCs (n=10), and normal fallopian tube (n=9) samples. Kaplan-Meier survival plots were used to estimate the impact of SMO expression on patients‘ overall survival (OS).

Results SMO nuclear expression was significantly higher in HGSCs and LGSCs compared with the fallopian tube samples (p=0.010 and p=0.003, respectively). LGSCs, compared with normal ovarian tissue, exhibited higher total, cytoplasmic/membrane and nuclear expression (p=0.000, p=0.001 and p=0.000, respectively). Comparing HGSCs and LGSCs, significantly higher total and cytoplasmic/membrane expression was found in HGSC (p=0.026 and p=0.030, respectively). SMO gene promoter was unmethylated in both LGSCs and HGSCs as well as in fallopian tube. In addition, the SMO protein expression had no significant impact on patients‘ OS (p=0.07).

Conclusion Our data indicate the lack of SMO gene promoter methylation while a significant overexpression (particularly nuclear) of SMO protein characterized a substantial proportion of serous ovarian carcinomas. Further functional studies should elucidate the clinical relevance of these findings.

Disclosure Nothing to disclose.

https://doi.org/10.1136/ijgc-2019-ESGO.969

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.